A second taxane that works after docetaxel and beat a second hormone pill head-to-head (CARD).
Cabazitaxel is a taxane with low affinity for the P-glycoprotein efflux pump, so it remains active in docetaxel-resistant disease. It is used in metastatic castration-resistant prostate cancer after docetaxel, with neutropenia as its main toxicity. TROPIC (2010) showed an overall survival benefit after docetaxel, and CARD (2019) showed it was superior to switching to a second androgen receptor pathway inhibitor in men who had already had one ARPI and docetaxel. It served as the comparator in TheraP, where it lost to 177Lu-PSMA-617 on PSA50 response (66% versus 37%) although overall survival was similar (HR 0.97), and in XALute against the T-cell engager xaluritamig. Its place relative to radioligands and T-cell engagers is therefore still being worked out. For a newcomer, it is the second taxane that works after docetaxel and beat a second hormone pill head-to-head.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Taxane with low P-glycoprotein affinity, active in docetaxel-resistant disease.
1.Cabazitaxel slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Generics entered the US market between 2021 and 2024 after patent litigation.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments. Plans typically require prior docetaxel.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA391 · SMC advice: cabazitaxel. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Region | Year | Indication |
|---|---|---|
| US | 2010 | mCRPC after docetaxel |
Read for the class this product belongs to (taxanes) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Cabazitaxel" OR ABSTRACT:"Cabazitaxel" OR TITLE:"Jevtana" OR ABSTRACT:"Jevtana") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cabazitaxel, not a curated reading list.
Shares FIRSTANA, TROPIC, What follows what in castration-resistant prostate cancer, Sanofi.
Shares XALute, A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate , Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel, TheraP (ANZUP 1603), Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer, Metastatic castration-resistant prostate cancer.
Shares CARD, TheraP (ANZUP 1603), What follows what in castration-resistant prostate cancer, Prostate cancer drugs in England: what NICE recommends, and what it refuses.
Shares CARD, TheraP (ANZUP 1603), What follows what in castration-resistant prostate cancer, Metastatic castration-resistant prostate cancer.
Shares What follows what in castration-resistant prostate cancer, Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer, Prostate cancer drugs in England: what NICE recommends, and what it refuses, Metastatic castration-resistant prostate cancer.
Shares CARD, What follows what in castration-resistant prostate cancer, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares AFFINITY, Metastatic castration-resistant prostate cancer, Cytotoxic chemotherapy, Prostate cancer.